Artiva Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| THREE MONTHS ENDED MARCH 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(20,311) | $(13,963) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 628 | 587 |
| Stock-based compensation | 2,052 | 1,406 |
| Change in fair value of SAFEs (including related party amounts of $0 and $217, respectively) | — | 268 |
| Accretion of discounts and amortization of premiums on investments, net | (723) | (368) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable (including related party amounts of $0 and $(251), respectively) | — | 215 |
| Other receivables (including related party amounts of $(11) and $(79), respectively) | (88) | (180) |
| Prepaid expenses and other current assets | (750) | (936) |
| Other long-term assets | 254 | 31 |
| Accounts payable (including related party amounts of $(270) and $772, respectively) | 41 | 851 |
| Accrued expenses (including related party amounts of $(632) and $(1,896), respectively) | (931) | (3,042) |
| Operating lease right-of-use asset and lease liabilities, net | (13) | 45 |
| Net cash used in operating activities | (19,841) | (15,086) |
| Investing activities: | ||
| Purchases of property and equipment | (511) | (18) |
| Purchases of investments | (18,518) | (6,200) |
| Maturities of investments | 29,000 | 16,000 |
| Net cash provided by investing activities | 9,971 | 9,782 |
| Financing activities: | ||
| Proceeds from exercise of stock options | 138 | — |
| Proceeds from purchase of ESPP shares | 134 | — |
| Payments on finance leases | (33) | — |
| Net cash provided by financing activities | 239 | — |
| Net decrease in cash, cash equivalents and restricted cash | (9,631) | (5,304) |
| Cash, cash equivalents and restricted cash at beginning of period | 40,493 | 53,762 |
| Cash, cash equivalents and restricted cash at end of period | $30,862 | $48,458 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $30,401 | $48,200 |
| Restricted cash | 461 | 258 |
| Total cash, cash equivalents and restricted cash | $30,862 | $48,458 |
| Supplemental disclosures of noncash activities: | ||
| Right-of-use asset obtained in exchange for new operating lease liability | $442 | $— |
| Property and equipment purchases in accounts payable and accrued expenses | $882 | $13 |
| Deferred offering costs in accounts payable and accrued expenses | $— | $286 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.